Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of KLH-2109 in endometriosis
jRCT2031250147Phase 3Active, not recruiting
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of linzagolix in endometriosis (4 arms), sponsored by Kissei Pharmaceutical Co., Ltd. Primary endpoint: Change in maximum NRS score for pelvic pain at 12 weeks. Started Jun 2025; status: active, not recruiting.
02
Drugs
linzagolix
03
Conditions
endometriosis
Beyond the preview
Go deeper on jRCT2031250147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250147.